Physician profile
Brian C Baumann
NPI 1841559945
$203,786.16
in general payments reported to CMS, 2019-2025
19 companies · $9,036 in 2025
The $9,036 reported for 2025 was more than what 96% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $5,085 · 2021: $16K · 2022: $13K · 2023: $126K · 2024: $35K · 2025: $9,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $154K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,818 · Travel and Lodging: $2,757 · Honoraria: $2,100 · Food and Beverage: $1,620 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $154,014.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,817.50 |
| Travel and Lodging | $2,756.85 |
| Honoraria | $2,100.00 |
| Food and Beverage | $1,620.28 |
| Education | $148.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $110,950.08 | 2019-2025 | Spaceoar Vue System - 10ml, Spaceoar System, General - Therapies |
| Siemens Medical Solutions USA, INC. | $70,946.50 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $6,930.00 | 2020-2021 | |
| Myovant Sciences INC. | $4,850.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $3,001.95 | 2023-2025 | Lutathera |
| Mevion_medical_systems_inc | $3,000.00 | 2020-2021 | |
| Blue Earth Diagnostics | $2,100.00 | 2023 | |
| Merck Sharp & Dohme LLC | $1,134.61 | 2020-2025 | Keytruda, Welireg |
| Astellas Pharma US INC | $178.47 | 2025 | Xtandi |
| Janssen Biotech, INC. | $138.25 | 2019-2025 | Erleada |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2019 | |
| Tactile Systems Technology INC | $105.85 | 2025 | Nimbl, Flexitouch Plus |
| Civatech Oncology, INC. | $78.15 | 2019 | |
| Sumitomo Pharma America, INC. | $74.07 | 2025 | Orgovyx |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.62 | 2024 | |
| Tolmar, INC. | $14.72 | 2023 | |
| Pharmaand Gmbh | $12.89 | 2025 | Rubraca |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Baumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.